市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Belite Bio, Inc | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 5.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.25 |
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 53.93% |
| 机构持股比例 | 0.75% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,077,219 |
| Maverick Capital Ltd | 30 Jun 2026 | 396,311 |
| Eventide Asset Management, Llc | 30 Jun 2026 | 390,829 |
| Holocene Advisors, Lp | 30 Jun 2026 | 251,035 |
| Mpm Bioimpact Llc | 30 Jun 2026 | 137,208 |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CHUANG HAO-YUAN | - | 192.85 | -17,962 | -3,463,972 |
| LIN YU-HSIN | - | 192.85 | -26,000 | -5,014,100 |
| 累积净数量 | -43,962 | |||
| 累积净值 ($) | -8,478,072 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 192.85 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| CHUANG HAO-YUAN | 职员 | 08 Sep 2026 | 自动卖出 (-) | 17,962 | 192.85 | 3,463,972 |
| LIN YU-HSIN | 职员 | 08 Sep 2026 | 自动卖出 (-) | 26,000 | 192.85 | 5,014,100 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合